Logotype for Kuros Biosciences AG

Kuros Biosciences (KURN) investor relations material

Kuros Biosciences H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kuros Biosciences AG
H1 2025 earnings summary14 Aug, 2025

Executive summary

  • Achieved 78% year-over-year revenue growth in H1 2025, reaching USD 63.5 million, with first-ever operating profit of USD 3.5 million and strong momentum in MagnetOs sales and international expansion.

  • Strong commercial execution in spine and extremities segments, supported by the Medtronic partnership, new product launches like the MIS applicator, and significant U.S. and international market share gains.

  • Expanded U.S. presence with new headquarters and production facility, and advanced global reach through regulatory approvals in Brazil, Lebanon, and ongoing registrations in multiple countries.

  • Hosted inaugural Capital Markets Day, strengthened brand recognition, and increased sales agent and hospital penetration.

  • Discontinued Pharmaceuticals segment, integrating legacy activities into the Legacy Portfolio.

Financial highlights

  • H1 2025 revenue reached USD 63.5 million, up from USD 35.7 million in H1 2024, with gross profit of USD 56.3 million and gross margin exceeding 88%.

  • Achieved first-time operating profit (EBIT) of USD 3.5 million and adjusted EBITDA of USD 7.8 million (margin 11.6–12.9%).

  • Robust cash and funds available for operations totaled USD 18.4–45.3 million as of June 30, 2025.

  • Cash flow now sufficient to fund organic growth, CapEx, and working capital internally.

  • Net loss for the period was USD 2.0 million, mainly due to higher finance expenses.

Outlook and guidance

  • Targeting at least 60% sales growth in 2025, with H2 expected to follow historical phasing and sales projected at USD 220–250 million by 2027.

  • Margin improvement expected to continue gradually, with ongoing investments in digitization, automation, and innovation.

  • New U.S. production facility in Atlanta scheduled to open in H2 2026, supporting further expansion.

  • Anticipates full commercial launch of MagnetOs MIS system in the U.S. in fall 2025.

  • Ongoing supply chain redesign to optimize tariffs, taxes, and de-risk operations.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Kuros Biosciences earnings date

Logotype for Kuros Biosciences AG
Q3 2025 TU16 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Kuros Biosciences earnings date

Logotype for Kuros Biosciences AG
Q3 2025 TU16 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Kuros Biosciences AG, operating under the ticker KURN, is a biotechnology company dedicated to discovering, developing, and delivering innovative fusion technologies for bone grafting. Founded as a spin-off from the Swiss Federal Institute of Technology in Zurich in 2000, Kuros Biosciences has established a significant presence in the field of tissue repair and regeneration. The company's flagship product line, MagnetOs, is designed for applications in spinal fusion, trauma, fracture repair, and as surgical sealants. The company is headquartered in Zurich, Switzerland, and its shares are listed on SIX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage